TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European ...

Congress 2024 will be held in Barcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd?"Kelun-Biotech", 6990.HK?will present the following results of ...

Developed by Moderna Pharmaceuticals-the same company that made headlines with its Covid-19 vaccine-the jab, known as mRNA-4359, is designed to activate the body's immune system to identify and ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

Washington (AFP) – An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease symptoms and duration, according to an animal study ...

Moderna’s mRNA cancer vaccine for solid tumours shows early signs of promise in interim data from a Phase I study. The messenger ribonucleic acid (mRNA) specialist announced the vaccine has ...